

Chitra Upadhyay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4561497/publications.pdf>

Version: 2024-02-01

19
papers

346
citations

933264

10
h-index

887953

17
g-index

23
all docs

23
docs citations

23
times ranked

611
citing authors

#	ARTICLE	IF	CITATIONS
1	Distinct Mechanisms Regulate Exposure of Neutralizing Epitopes in the V2 and V3 Loops of HIV-1 Envelope. <i>Journal of Virology</i> , 2014, 88, 12853-12865.	1.5	53
2	Identification of sequence changes responsible for the attenuation of avian infectious bronchitis virus strain Arkansas DPI. <i>Archives of Virology</i> , 2009, 154, 495-499.	0.9	41
3	Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response. <i>Journal of Virology</i> , 2016, 90, 10993-11006.	1.5	33
4	Formation of subviral particles of the capsid protein VP2 of infectious bursal disease virus and its application in serological diagnosis. <i>Journal of Virological Methods</i> , 2009, 157, 84-89.	1.0	29
5	Detection of Antibody Responses Against SARS-CoV-2 in Plasma and Saliva From Vaccinated and Infected Individuals. <i>Frontiers in Immunology</i> , 2021, 12, 759688.	2.2	29
6	Modulation of Antibody Responses to the V1V2 and V3 Regions of HIV-1 Envelope by Immune Complex Vaccines. <i>Frontiers in Immunology</i> , 2018, 9, 2441.	2.2	22
7	Alterations of HIV-1 envelope phenotype and antibody-mediated neutralization by signal peptide mutations. <i>PLoS Pathogens</i> , 2018, 14, e1006812.	2.1	20
8	Signal peptide of HIV-1 envelope modulates glycosylation impacting exposure of V1V2 and other epitopes. <i>PLoS Pathogens</i> , 2020, 16, e1009185.	2.1	14
9	Recombinant Infectious Bursal Disease Virus Carrying Hepatitis C Virus Epitopes. <i>Journal of Virology</i> , 2011, 85, 1408-1414.	1.5	13
10	P2X1 Selective Antagonists Block HIV-1 Infection through Inhibition of Envelope Conformation-Dependent Fusion. <i>Journal of Virology</i> , 2020, 94, .	1.5	12
11	Heterogeneity in glycan composition on the surface of HIV-1 envelope determines virus sensitivity to lectins. <i>PLoS ONE</i> , 2018, 13, e0194498.	1.1	12
12	HIV-1 Envelope Glycan Composition as a Key Determinant of Efficient Virus Transmission via DC-SIGN and Resistance to Inhibitory Lectins. <i>IScience</i> , 2019, 21, 413-427.	1.9	11
13	Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies. <i>PLoS ONE</i> , 2015, 10, e0141233.	1.1	10
14	Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL. <i>Journal of Virology</i> , 2015, 89, 9090-9102.	1.5	10
15	Short Communication: Man α 1-2Man-Binding Anti-HIV Lectins Enhance the Exposure of V2i and V3 Crown Neutralization Epitopes on the V1/V2 and V3 Hypervariable Loops of HIV-1 Envelope. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 941-945.	0.5	10
16	Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice. <i>PLoS Pathogens</i> , 2022, 18, e1010183.	2.1	8
17	HIV-1 Envelope Glycosylation and the Signal Peptide. <i>Vaccines</i> , 2021, 9, 176.	2.1	5
18	A cross-reactive mouse monoclonal antibody against rhinovirus mediates phagocytosis in vitro. <i>Scientific Reports</i> , 2020, 10, 9750.	1.6	4

#	ARTICLE	IF	CITATIONS
19	Dual Role of HIV-1 Envelope Signal Peptide in Immune Evasion. <i>Viruses</i> , 2022, 14, 808.	1.5	0